Albert Chiou, MD, MBA, discusses early clinical data on soquelitinib for atopic dermatitis, highlighting its targeted ITK inhibition, dose-dependent efficacy, favorable safety profile, and more.
Albert Chiou, MD, MBA
Advertisement
Albert Chiou, MD, MBA, is a board-certified dermatologist and clinical associate professor of dermatology at the Stanford University School of Medicine in California.
Articles by Albert Chiou, MD, MBA
Advertisement
Latest Updated Articles
Expert Insights Highlight Novel ITK Inhibition With Soquelitinib for ADPublished: May 19th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
